ADXS (Ayala Pharmaceuticals) Interest Expense : $-16.02 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ayala Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ayala Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was $ -15.79 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ayala Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $ -8.78 Mil. Ayala Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $ -15.79 Mil. Ayala Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ayala Pharmaceuticals Interest Expense Historical Data

The historical data trend for Ayala Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ayala Pharmaceuticals Interest Expense Chart

Ayala Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.26

-15.75

Ayala Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-0.09	-0.14	-15.79

Ayala Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.02 Mil.

Ayala Pharmaceuticals (OTCPK:ADXS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ayala Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-15.79 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-8.78 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $8.15 Mil.

Ayala Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Ayala Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Ayala Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ayala Pharmaceuticals Inc (OTCPK:ADXS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 08852

Website

https://www.ayalapharma.com

Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.

Executives

Yair Chaim Schindel	other: shareholder of 10% holder	YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
Roni Mamluk	director, officer: CEO	CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
Gary B. Gordon	officer: Chief Medical Officer	C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104
David Sidransky	director	JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Vered Bisker-leib	director	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p.	10 percent owner	4 OPPENHEIMER ST., REHOVOT L3 7670104
Harel Insurance Co Ltd	10 percent owner	ABBA HILLEL 3, RAMAT GAN L3 5211802
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Murray A Goldberg	director	2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Maimon Yossi	officer: CFO	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Harel Insurance Investments & Financial Services Ltd.	10 percent owner	HAREL HOUSE, 3 ABBA HILLEL ST., RAMAT GAN L3 52118
Todd Sone	director	C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104